Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on August 3, 2022, reporting events that occurred on July 29, 2022. The company is incorporated in Florida and its common stock trades on the NYSE American under the symbol OGEN.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
On July 29, 2022, the Compensation Committee and Board of Directors approved stock option awards under the Company's 2021 Equity Incentive Plan for two executive officers:
- Michael Sullivan (Chief Financial Officer): Awarded options to purchase 200,000 shares.
- Dr. Martin Handfield (Senior Vice President of Discovery Research): Awarded options to purchase 100,000 shares.
Terms of the Awards:
- Exercise Price: $0.3562 per share (closing price on the grant date).
- Vesting Schedule: Time-based vesting in equal annual installments over three years (33.3% on the first, second, and third anniversaries of the grant date).
- Change in Control: Awards include provisions for earlier vesting upon a change in control of the Company.
Guidance, Outlook, and Risks
The filing text does not provide financial guidance, outlook, management commentary on operations, or specific risk factors beyond the standard terms of the equity awards.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the 2021 Equity Incentive Plan to assess remaining capacity for future grants.
- Confirm the current market price of OGEN stock relative to the $0.3562 exercise price to evaluate the intrinsic value of these awards.
- Review the company's most recent 10-Q or 10-K for cash burn rates and liquidity status, as this 8-K does not contain financial performance data.